Profile data is unavailable for this security.
About the company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
- Revenue in CHF (TTM)1.65m
- Net income in CHF-10.56m
- Incorporated2007
- Employees23.00
- LocationAddex Therapeutics LtdChemin des Mines, 9PLAN-LES-OUATES 1202SwitzerlandCHE
- Phone+41 228841555
- Fax+41 228841556
- Websitehttps://www.addextherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Circa Group AS | 1.63m | -6.26m | 11.96m | 17.00 | -- | 0.4007 | -- | 7.34 | -0.6718 | -0.6718 | 0.1725 | 2.86 | 0.0403 | 5.46 | 0.9139 | 1,122,000.00 | -15.46 | -- | -19.96 | -- | 75.64 | -- | -383.72 | -- | 0.7097 | -- | 0.00 | -- | 41.73 | -- | -0.0491 | -- | -- | -- |
| Enorama Pharma AB | 115.83k | -3.81m | 11.97m | 5.00 | -- | 6.58 | -- | 103.34 | -1.16 | -1.16 | 0.0353 | 0.3858 | 0.0327 | 1.48 | 1.38 | 271,600.00 | -107.36 | -73.56 | -147.57 | -104.85 | -287.26 | 43.36 | -3,285.20 | -557.42 | 0.8487 | -16.95 | 0.0218 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
| StenoCare A/S | 545.18k | -2.23m | 12.01m | 9.00 | -- | 4.03 | -- | 22.04 | -1.13 | -1.13 | 0.2674 | 1.22 | 0.1285 | -- | 2.94 | -- | -52.62 | -28.16 | -70.34 | -35.47 | -- | -- | -409.55 | -371.06 | 1.04 | -5.56 | 0.2362 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| Xintela AB | 6.65k | -4.61m | 12.09m | -- | -- | 32.36 | -- | 1,817.33 | -0.1524 | -0.1524 | 0.0002 | 0.0077 | 0.0036 | -- | 0.0088 | -- | -252.09 | -181.06 | -1,065.04 | -391.61 | 100.00 | -- | -69,343.59 | -235,894.00 | -- | -50.47 | 0.00 | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -3.96m | 12.18m | 4.00 | -- | 15.82 | -- | -- | -0.1765 | -0.1765 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -256.08 | -125.42 | -351.79 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Proteome Sciences plc | 5.86m | -2.85m | 12.38m | 35.00 | -- | -- | -- | 2.11 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Kanabo Group PLC | 1.04m | -9.30m | 12.52m | 20.00 | -- | 1.43 | -- | 12.01 | -0.0137 | -0.0137 | 0.0017 | 0.0119 | 0.0785 | 11.11 | 28.41 | -- | -70.12 | -75.83 | -77.61 | -83.33 | 14.97 | -- | -893.30 | -1,267.35 | 4.96 | -10.43 | 0.035 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| Addex Therapeutics Ltd | 1.65m | -10.56m | 12.54m | 23.00 | -- | 7.43 | -- | 7.61 | -0.1433 | -0.1433 | 0.0222 | 0.0092 | 0.2549 | -- | 14.82 | 71,612.17 | -163.36 | -69.05 | -312.84 | -84.19 | -- | -- | -640.91 | -572.59 | -- | -34.12 | 0.2311 | -- | 13.99 | -24.47 | 49.26 | -- | -5.45 | -- |
| Arterra Bioscience SpA | 3.27m | 1.07m | 13.07m | 30.00 | 12.20 | 1.22 | 7.77 | 3.99 | 0.1624 | 0.1624 | 0.4985 | 1.62 | 0.263 | 1.18 | -- | -- | 8.57 | 10.57 | 9.44 | 12.30 | 55.03 | 60.57 | 32.57 | 34.31 | 7.47 | -- | -- | -- | -7.28 | 6.36 | -23.89 | 0.6056 | -- | -- |
| Celyad Oncology SA | 101.10k | -8.37m | 13.10m | 12.00 | -- | 2.10 | -- | 129.57 | -0.3287 | -0.3287 | 0.004 | 0.1522 | 0.0057 | -- | 0.1583 | 8,500.00 | -46.94 | -39.16 | -74.63 | -47.45 | 32.35 | 38.94 | -8,282.35 | -107,726.50 | -- | -156.61 | 0.1437 | -- | -- | -49.53 | 79.36 | -- | -11.95 | -- |
| Vo2 Cap Holding AB (publ) | 29.24m | 274.13k | 13.18m | 103.00 | 47.64 | 0.699 | 3.03 | 0.4509 | 0.0607 | 0.0607 | 6.50 | 4.13 | 0.7493 | -- | 7.03 | 3,328,282.00 | 0.7023 | -0.2564 | 0.9347 | -0.3839 | 34.62 | 23.36 | 0.9373 | -0.2409 | -- | 1.18 | 0.1564 | -- | -26.09 | 85.65 | -57.92 | -- | -17.96 | -- |
| Chill Brands Group PLC | 170.76k | -4.24m | 13.21m | 2.00 | -- | -- | -- | 77.35 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Medicofarma Biotech SA | 315.43k | -489.48k | 13.26m | -- | -- | 5.76 | -- | 42.03 | -0.031 | -0.031 | 0.02 | 0.1459 | 0.0866 | 5.56 | 2.83 | -- | -13.45 | -13.16 | -17.22 | -15.86 | 78.54 | 29.92 | -155.18 | -37.81 | 0.805 | -11.28 | 0.00 | -- | -82.34 | -31.48 | -68.11 | -- | -- | -- |
| Read Gene SA | 2.33m | -428.69k | 13.47m | 11.00 | -- | 13.15 | -- | 5.77 | -0.1954 | -0.1954 | 1.06 | 0.3741 | 0.666 | 48.81 | 4.51 | -- | -12.24 | -1.71 | -13.14 | -2.11 | 88.57 | 88.01 | -18.37 | -3.90 | 6.46 | -4.19 | -- | -- | 38.79 | 15.77 | -966.00 | -- | -- | -- |
| PMD Device Solutions AB | 2.44m | -3.09m | 13.51m | 1.00 | -- | -- | -- | 5.54 | -16.69 | -16.69 | 6.34 | -4.79 | 0.9465 | -- | 57.42 | -- | -119.63 | -- | -- | -- | 58.18 | -- | -126.39 | -- | 0.0505 | -3.00 | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Addex Therapeutics Ltd's reporting currency: Swiss Franc CHF
3.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2022 | 4.05m | 2.20% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 872.27k | 0.47% |
| Herculis Partners SAas of 31 Dec 2023 | 504.59k | 0.27% |
| Lombard Odier Asset Management (Switzerland) SAas of 29 Mar 2024 | 296.76k | 0.16% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 252.00k | 0.14% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 140.73k | 0.08% |
| BlackRock Asset Management Schweiz AGas of 08 May 2024 | 55.76k | 0.03% |
| Pictet Asset Management SAas of 31 Jan 2024 | 45.82k | 0.03% |
| Credit Suisse AGas of 31 Jan 2024 | 26.67k | 0.01% |
| DWS CH AGas of 28 Mar 2024 | 17.19k | 0.01% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
